AU516264B2 - Phthalazin-4-ylacetic acid derivatives - Google Patents

Phthalazin-4-ylacetic acid derivatives

Info

Publication number
AU516264B2
AU516264B2 AU42040/78A AU4204078A AU516264B2 AU 516264 B2 AU516264 B2 AU 516264B2 AU 42040/78 A AU42040/78 A AU 42040/78A AU 4204078 A AU4204078 A AU 4204078A AU 516264 B2 AU516264 B2 AU 516264B2
Authority
AU
Australia
Prior art keywords
phthalazin
acid derivatives
ylacetic acid
ylacetic
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU42040/78A
Other languages
English (en)
Other versions
AU4204078A (en
Inventor
D. R. and Wood R Brittain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Publication of AU4204078A publication Critical patent/AU4204078A/en
Application granted granted Critical
Publication of AU516264B2 publication Critical patent/AU516264B2/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU42040/78A 1977-12-29 1978-11-29 Phthalazin-4-ylacetic acid derivatives Expired AU516264B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB54142/77 1977-12-29
GB5414277 1977-12-29

Publications (2)

Publication Number Publication Date
AU4204078A AU4204078A (en) 1979-07-05
AU516264B2 true AU516264B2 (en) 1981-05-28

Family

ID=10470067

Family Applications (1)

Application Number Title Priority Date Filing Date
AU42040/78A Expired AU516264B2 (en) 1977-12-29 1978-11-29 Phthalazin-4-ylacetic acid derivatives

Country Status (31)

Country Link
US (2) US4251528A (en, 2012)
EP (1) EP0002895B1 (en, 2012)
JP (2) JPS5495582A (en, 2012)
AT (1) AT365581B (en, 2012)
AU (1) AU516264B2 (en, 2012)
BG (1) BG34336A3 (en, 2012)
CA (1) CA1107732A (en, 2012)
CS (1) CS241015B2 (en, 2012)
CY (1) CY1219A (en, 2012)
DD (1) DD141021A5 (en, 2012)
DE (1) DE2861170D1 (en, 2012)
DK (1) DK151253C (en, 2012)
ES (1) ES476496A1 (en, 2012)
FI (1) FI64357C (en, 2012)
GR (1) GR65303B (en, 2012)
HK (1) HK22484A (en, 2012)
HU (1) HU182585B (en, 2012)
IE (1) IE47592B1 (en, 2012)
IL (1) IL56099A0 (en, 2012)
IN (1) IN150196B (en, 2012)
IT (1) IT1110885B (en, 2012)
MY (1) MY8500359A (en, 2012)
NO (1) NO154346C (en, 2012)
NZ (1) NZ189034A (en, 2012)
PH (1) PH15435A (en, 2012)
PL (1) PL118443B1 (en, 2012)
PT (1) PT68956A (en, 2012)
SG (1) SG68683G (en, 2012)
SU (3) SU1087075A3 (en, 2012)
YU (3) YU41607B (en, 2012)
ZW (1) ZW24978A1 (en, 2012)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
CA1143733A (en) * 1979-07-31 1983-03-29 Masao Yoshida Producing 7-alkoxycarbonyl-6,8-dimethyl-4- hydroxymethyl-1-phthalazone and intermediates
US4762839A (en) * 1985-06-06 1988-08-09 Tanabe Seiyaku Co., Ltd. Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications
ES2032749T3 (es) * 1985-11-07 1993-03-01 Pfizer Inc. Acidos oxoftalazinil-aceticos heterociclicos.
JPS63132889A (ja) * 1986-11-21 1988-06-04 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
US5011840A (en) * 1986-11-24 1991-04-30 Pfizer Inc. Imidazolidinedione derivatives in diabetes treatment
GB8704569D0 (en) * 1987-02-26 1987-04-01 Ici America Inc Therapeutic agent
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
DK607188A (da) * 1987-11-02 1989-06-22 Merck & Co Inc Tablet indeholdende en phthalazineddikesyreforbindelse
IL88150A0 (en) * 1987-11-02 1989-06-30 Merck & Co Inc Pharmaceutical tablet compositions containing phthalizine acetic acid compounds
US4880928A (en) * 1987-12-21 1989-11-14 Merck & Co., Inc. Process for the preparation of 3-((4-bromo-2-fluorophenyl)methyl)-3,4-dihydro-4-oxo-1-phthalazine-acetic acid
US4940791A (en) * 1988-02-29 1990-07-10 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel hydrazine containing intermediate
US4904782A (en) * 1988-02-29 1990-02-27 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
EP0397930A1 (en) * 1989-05-18 1990-11-22 Merck & Co. Inc. Process for the preparation of 3-[(4-bromo-2-fluorophenyl) methyl]-3,4-dihydro-4-oxo-1-phthalazineacetic acid
FR2647676A1 (fr) * 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
WO1991009019A1 (en) * 1989-12-15 1991-06-27 Pfizer Inc. Substituted oxophthalazinyl acetic acids and analogs thereof
US5037831A (en) * 1990-05-21 1991-08-06 American Home Products Corporation Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
FR2682108B1 (fr) * 1991-10-07 1994-01-07 Lipha Acide 3,4-dihydro-4-oxo-3(prop-2-enyl)-1-phtalazineacetiques et derives, leurs preparations et medicaments les contenant.
US5728704A (en) * 1992-09-28 1998-03-17 Pfizer Inc. Substituted pyridmidines for control of diabetic complications
CA2147504A1 (en) * 1992-11-02 1994-05-11 Prasun K. Chakravarty Substituted phthalazinones as neurotensin antagonists
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
WO1995003053A1 (en) * 1993-07-26 1995-02-02 Fujisawa Pharmaceutical Co., Ltd. Oxophthalazines for treating cachexia
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
WO1998042324A2 (en) * 1997-03-21 1998-10-01 The Regents Of The University Of California Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors
ZA983170B (en) * 1997-04-15 1999-10-15 Csir Pharmaceutical compositions having appetite suppressant activity.
TR200002869T2 (tr) * 1998-03-31 2000-12-21 The Institute For Pharmaceutical Discovery,Inc. İkame edilmiş indolealkonik asitler.
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
GB2355657B (en) * 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
DE19963607B4 (de) * 1999-12-23 2005-12-15 Schering Ag Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
BR0115776A (pt) * 2000-11-30 2004-01-13 Pfizer Prod Inc Combinações de agonistas de gaba e inibidores da aldose redutase
ES2240657T3 (es) 2001-02-28 2005-10-16 Pfizer Products Inc. Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa.
ATE286049T1 (de) 2001-03-30 2005-01-15 Pfizer Prod Inc Pyridazinonaldose reductase inhibitoren
HUP0303920A3 (en) * 2001-04-30 2004-07-28 Pfizer Prod Inc Pharmaceutical compositions containing combinations of aldose reductase inhibitor pyridazinons and cyclooxygenase 2 inhibitors
AU761191B2 (en) 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
US20050209237A1 (en) * 2002-04-30 2005-09-22 Brazzell Romulus K Method for decreasing capillary permeability in the retina
MXPA05001011A (es) * 2002-07-26 2005-06-08 Inst For Pharm Discovery Inc Derivado de acidos indolalcanoicos substituidos y formulaciones que lo contienen para uso en tratamiento de complicaciones diabeticas.
US7572910B2 (en) * 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
JP4838582B2 (ja) * 2004-12-27 2011-12-14 岐阜プラスチック工業株式会社 台車用本体
JP2010520913A (ja) 2007-03-12 2010-06-17 サズセ アーペーエス ルイボスの抗糖尿病性抽出物
EP2848252A3 (en) 2007-03-23 2015-06-17 The Board of Regents of the University of Texas System Aldose reductase inhibitors for use in treating uveitis
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
WO2012088525A2 (en) 2010-12-23 2012-06-28 The Board Of Regents Of The University Of Texas System Methods for treating copd
JP6357292B2 (ja) * 2012-12-14 2018-07-11 フューシス セラピューティクス、インク． Ｃｎｋｓｒ１を阻害するための方法及び組成物
CA2983260C (en) 2015-04-20 2024-01-23 Phusis Therapeutics, Inc. Sulfonamide compounds, compositions and methods for inhibiting cnksr1
US12090142B2 (en) 2018-02-22 2024-09-17 Board Of Regents, The University Of Texas System Combination therapy for the treatment of cancer
WO2020071386A1 (ja) * 2018-10-04 2020-04-09 日東電工株式会社 耐熱離型シート及び熱圧着方法
JP6751974B1 (ja) * 2019-10-16 2020-09-09 株式会社コバヤシ 離型フィルム及び離型フィルムの製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833579A (en) * 1935-11-11 1974-09-03 Inoue Michiro 4-carbamoyl phthalazones
JPS5116430B2 (en, 2012) * 1971-08-05 1976-05-24
GB1398549A (en) * 1972-11-06 1975-06-25 Boots Co Ltd Phthalazine derivatives and their use in pharmaceutical compo sitions
AR205004A1 (es) * 1973-10-30 1976-03-31 Ishikawa M Procedimiento para preparar derivados de 6,8-dialquil-7-alcoxi-carbonil-4-hidroximetil-1-ftalazona y la 7,8-lactona
DE2451117A1 (de) * 1973-10-31 1975-05-22 Boots Co Ltd Therapeutisch wirksame verbindungen
IE43079B1 (en) * 1975-03-20 1980-12-17 Ici Ltd Quinolone derivatives
GB1502312A (en) 1975-03-20 1978-03-01 Ici Ltd Quinolone derivatives
JPS5214788A (en) * 1975-07-21 1977-02-03 Fuji Photo Film Co Ltd Process for preparing phthalazinone and its derivatives
NL7702763A (nl) * 1976-03-18 1977-09-20 Takio Shimamoto En Masayuki Is Werkwijze voor de bereiding van thromboxaan- -antagonisten en van preparaten die deze stof- fen bevatten.
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4293553A (en) * 1978-08-11 1981-10-06 Masayuki Ishikawa 1-Phthalazone derivatives, and use thereof

Also Published As

Publication number Publication date
NO154346B (no) 1986-05-26
SU1087075A3 (ru) 1984-04-15
ATA937678A (de) 1981-06-15
IN150196B (en, 2012) 1982-08-14
YU41607B (en) 1987-12-31
PH15435A (en) 1983-01-18
ES476496A1 (es) 1979-04-16
IT1110885B (it) 1986-01-06
JPS6326110B2 (en, 2012) 1988-05-27
YU232082A (en) 1983-01-21
FI64357B (fi) 1983-07-29
PT68956A (en) 1979-01-01
MY8500359A (en) 1985-12-31
CA1107732A (en) 1981-08-25
YU232182A (en) 1983-01-21
JPH0262532B2 (en, 2012) 1990-12-26
IL56099A0 (en) 1979-01-31
HU182585B (en) 1984-02-28
EP0002895B1 (en) 1981-10-14
DK541878A (da) 1979-06-30
FI64357C (fi) 1983-11-10
US4251528A (en) 1981-02-17
CS241015B2 (en) 1986-03-13
NZ189034A (en) 1981-11-19
US4393062A (en) 1983-07-12
BG34336A3 (bg) 1983-08-15
IE782337L (en) 1979-06-29
EP0002895A1 (en) 1979-07-11
SU1272984A3 (ru) 1986-11-23
IT7852480A0 (it) 1978-12-28
NO784397L (no) 1979-07-02
SG68683G (en) 1984-08-03
SU1072803A3 (ru) 1984-02-07
NO154346C (no) 1986-09-03
AU4204078A (en) 1979-07-05
PL118443B1 (en) 1981-10-31
YU42054B (en) 1988-04-30
JPS5495582A (en) 1979-07-28
ZW24978A1 (en) 1980-10-22
YU312778A (en) 1983-01-21
AT365581B (de) 1982-01-25
DK151253C (da) 1988-05-16
DK151253B (da) 1987-11-16
JPS63119469A (ja) 1988-05-24
DD141021A5 (de) 1980-04-09
IE47592B1 (en) 1984-05-02
HK22484A (en) 1984-03-23
CY1219A (en) 1984-04-06
YU42807B (en) 1988-12-31
DE2861170D1 (en) 1981-12-24
GR65303B (en) 1980-08-01
FI783844A7 (fi) 1979-06-30

Similar Documents

Publication Publication Date Title
AU516264B2 (en) Phthalazin-4-ylacetic acid derivatives
AU527127B2 (en) D-(alpha-phenoxy)-prodionic acid derivatives
AU4220078A (en) Acylanilide derivatives
AU520784B2 (en) Interphenylene 9-thia-oxo-12-azaprostand acid derivatives
AU3900678A (en) Tripherylalkene derivatives
AU3938978A (en) Thienothiazine derivatives
AU4208778A (en) Thiohydantion derivatives
AU523346B2 (en) Cephalosporanic acid derivatives
AU3229078A (en) M-trifluoromethylphenylpiperazine derivatives
AU523183B2 (en) Ethoxygquin derivatives
AU3319078A (en) Antioestrogenic phenylbut-1-ene derivatives
AU3268778A (en) Meta-sulfonamido-benzamide derivatives
AU3285878A (en) Oxadiazolopyrimidine derivatives
AU3931878A (en) 25-alkylcholesterol derivatives
AU516223B2 (en) 2-hydrazono propionic acid derivatives
AU522514B2 (en) 7p-acylamido-3-cephem-4-carboxylic acid derivatives
AU521514B2 (en) 6-azaoligocycloakyl-methylene amino-penicillanic acid derivatives
AU3245878A (en) Phenylacycloakane derivatives
AU3835678A (en) Pyranochromone derivatives
AU517387B2 (en) Tetracyclononane derivatives
AU524985B2 (en) O-aminodeoxyclayulanic acid derivatives
AU3598578A (en) Fortimicing derivatives
AU519473B2 (en) Oxaminic acid derivatives
AU513904B2 (en) 2-trichloromethyl-4-nitrobenzenesulfenic acid derivatives
AU519232B2 (en) Clavulanic acid derivatives